GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lifecore Biomedical Inc (NAS:LFCR) » Definitions » Beneish M-Score

Lifecore Biomedical (Lifecore Biomedical) Beneish M-Score : -3.45 (As of Apr. 26, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Lifecore Biomedical Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.45 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Lifecore Biomedical's Beneish M-Score or its related term are showing as below:

LFCR' s Beneish M-Score Range Over the Past 10 Years
Min: -4.42   Med: -2.59   Max: -1.15
Current: -3.45

During the past 13 years, the highest Beneish M-Score of Lifecore Biomedical was -1.15. The lowest was -4.42. And the median was -2.59.


Lifecore Biomedical Beneish M-Score Historical Data

The historical data trend for Lifecore Biomedical's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lifecore Biomedical Beneish M-Score Chart

Lifecore Biomedical Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.51 -1.15 -2.12 -4.42 -3.45

Lifecore Biomedical Quarterly Data
Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.42 -4.78 -3.76 -4.21 -3.45

Competitive Comparison of Lifecore Biomedical's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Lifecore Biomedical's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lifecore Biomedical's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lifecore Biomedical's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Lifecore Biomedical's Beneish M-Score falls into.



Lifecore Biomedical Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Lifecore Biomedical for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8042+0.528 * 1.5426+0.404 * 0.6728+0.892 * 0.942+0.115 * 1.4519
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.1036+4.679 * -0.206614-0.327 * 0.8825
=-3.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (May23) TTM:Last Year (May22) TTM:
Total Receivables was $29.0 Mil.
Revenue was 25.521 + 27.6 + 38.802 + 43.355 = $135.3 Mil.
Gross Profit was 8.415 + 5.978 + 7.108 + 6.252 = $27.8 Mil.
Total Current Assets was $93.9 Mil.
Total Assets was $253.5 Mil.
Property, Plant and Equipment(Net PPE) was $138.7 Mil.
Depreciation, Depletion and Amortization(DDA) was $13.3 Mil.
Selling, General, & Admin. Expense(SGA) was $40.2 Mil.
Total Current Liabilities was $39.3 Mil.
Long-Term Debt & Capital Lease Obligation was $110.8 Mil.
Net Income was -35.571 + -40.192 + -12.449 + -11.351 = $-99.6 Mil.
Non Operating Income was -23.413 + -2.637 + -2.459 + -1.227 = $-29.7 Mil.
Cash Flow from Operations was -0.272 + -12.688 + -2.948 + -1.533 = $-17.4 Mil.
Total Receivables was $38.3 Mil.
Revenue was 21.13 + 37.399 + 43.452 + 41.632 = $143.6 Mil.
Gross Profit was 7.433 + 12.866 + 14.715 + 10.435 = $45.4 Mil.
Total Current Assets was $116.7 Mil.
Total Assets was $274.7 Mil.
Property, Plant and Equipment(Net PPE) was $124.2 Mil.
Depreciation, Depletion and Amortization(DDA) was $18.1 Mil.
Selling, General, & Admin. Expense(SGA) was $38.6 Mil.
Total Current Liabilities was $176.6 Mil.
Long-Term Debt & Capital Lease Obligation was $7.7 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(29.024 / 135.278) / (38.314 / 143.613)
=0.214551 / 0.266786
=0.8042

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(45.449 / 143.613) / (27.753 / 135.278)
=0.316469 / 0.205155
=1.5426

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (93.875 + 138.672) / 253.545) / (1 - (116.668 + 124.223) / 274.703)
=0.082818 / 0.123086
=0.6728

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=135.278 / 143.613
=0.942

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(18.061 / (18.061 + 124.223)) / (13.285 / (13.285 + 138.672))
=0.126936 / 0.087426
=1.4519

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(40.174 / 135.278) / (38.645 / 143.613)
=0.296974 / 0.269091
=1.1036

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((110.774 + 39.289) / 253.545) / ((7.658 + 176.581) / 274.703)
=0.591859 / 0.670684
=0.8825

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-99.563 - -29.736 - -17.441) / 253.545
=-0.206614

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Lifecore Biomedical has a M-score of -3.45 suggests that the company is unlikely to be a manipulator.


Lifecore Biomedical Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Lifecore Biomedical's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Lifecore Biomedical (Lifecore Biomedical) Business Description

Traded in Other Exchanges
N/A
Address
3515 Lyman Boulevard, Chaska, MN, USA, 55318
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid.
Executives
Raymond T. White director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, Llc director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners Holdings, Llc director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, L.p. Ii director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, L.p. I director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners Asset Management, Llc director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Christopher S Kiper director 12121 WILSHIRE BLVD, SUITE 1240, LOS ANGELES CA 90025
Nathaniel Calloway director C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734
Wynnefield Partners Small Cap Value Lp I 10 percent owner 450 SEVENTH AVENUE, SUITE 509, NEW YORK NY 10123
Raymond H Diradoorian director C/O LANDEC CORPORATION, 2811 AIRPARK DRIVE, SANTA MARIA CA 93455
Joshua Schechter director C/O THE PANTRY, INC., 305 GREGSON DRIVE, CARY NC 27511
Patrick D Walsh director 14282 FRANKLIN AVE., TUSTIN CA 92780
John D Morberg officer: Chief Financial Officer C/O LANDEC CORPORATION, 2811 AIRPARK DRIVE, SANTA MARIA CA 93455
Albert D. Bolles director CONAGRA FOODS, INC., ONE CONAGRA DRIVE, MS 1-330, OMAHA NE 68102
James G Hall officer: Executive Vice President 3515 LYMAN BLVD., CHASKA MN 55318